AbCellera ^Company

AbCellera is focusing on Anti-SAR-CoV-2 Antibodies together with the company Eli Lilly, work that they are developing using the AbCellera’s rapid pandemic response platform. Both companies said March 13 that they will partner to co-develop the most promising of 500+ unique fully human antibody sequences identified in a blood sample from one of the first U.S. patients to recover from COVID-19.